Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Sachin Apurwa"'
Autor:
Sewanti Limaye, Simon Chowdhury, Nitesh Rohatgi, Anantbhushan Ranade, Nelofer Syed, Johann Riedemann, Darshana Patil, Dadasaheb Akolkar, Vineet Datta, Shoeb Patel, Rohit Chougule, Pradyumna Shejwalkar, Kiran Bendale, Sachin Apurwa, Stefan Schuster, Jinumary John, Ajay Srinivasan, Rajan Datar
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9116-9127 (2023)
Abstract Background The low specificity of serum PSA resulting in the inability to effectively differentiate prostate cancer from benign prostate conditions is a persistent clinical challenge. The low sensitivity of serum PSA results in false negativ
Externí odkaz:
https://doaj.org/article/9df8191d60ad4d7aa84a5cf4660a8892
Autor:
Darshana Patil, Dadasaheb Akolkar, Rajnish Nagarkar, Navin Srivastava, Vineet Datta, Sanket Patil, Sachin Apurwa, Ajay Srinivasan, Rajan Datar
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposeThe selection of safe and efficacious anticancer regimens for treatment of patients with broadly refractory metastatic cancers remains a clinical challenge. Such patients are often fatigued by toxicities of prior failed treatments and may have
Externí odkaz:
https://doaj.org/article/0fcb22bfe9da4aee9e5ccfdaf150b89e
Autor:
Raymond Page, Darshana Patil, Dadasaheb Akolkar, Sudha S Murthy, Kiran Bendale, Revati Patil, Pradeep Fulmali, Pooja Fulmali, Archana Adhav, Sneha Puranik, Sachin Apurwa, Vineet Datta, Chirantan Bose, Stefan Schuster, Jinumary John, Ajay Srinivasan, Rajan Datar
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0270139 (2022)
Biomarker directed selection of targeted anti-neoplastic agents such as immune checkpoint inhibitors, small molecule inhibitors and monoclonal antibodies form an important aspect of cancer treatment. Immunohistochemistry (IHC) analysis of the tumor t
Externí odkaz:
https://doaj.org/article/6eec000a3c9b43498bccf8b4278e997a
Autor:
Sewanti Limaye, Darshana Patil, Dadasaheb Akolkar, Navin Srivastava, Revati Patil, Sachin Apurwa, Sanket Patil, Jinumary John, Rahul Gosavi, Prabhu Nesargikar, Prashant Kumar, Vineet Datta, Chirantan Bose, Zarrine Raazi, Ajay Srinivasan, Rajan Datar
Publikováno v:
Clinical Case Reports, Vol 9, Iss 11, Pp n/a-n/a (2021)
Abstract Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatme
Externí odkaz:
https://doaj.org/article/65674c3e054d4917ac8f5a42efa27c35
Autor:
Timothy Crook, Robert Leonard, Kefah Mokbel, Alastair Thompson, Michael Michell, Raymond Page, Ashok Vaid, Ravi Mehrotra, Anantbhushan Ranade, Sewanti Limaye, Darshana Patil, Dadasaheb Akolkar, Vineet Datta, Pradip Fulmali, Sachin Apurwa, Stefan Schuster, Ajay Srinivasan, Rajan Datar
Publikováno v:
Cancers, Vol 14, Iss 14, p 3341 (2022)
Background: The early detection of breast cancer (BrC) is associated with improved survival. We describe a blood-based breast cancer detection test based on functional enrichment of breast-adenocarcinoma-associated circulating tumor cells (BrAD-CTCs)
Externí odkaz:
https://doaj.org/article/513084339a6d4fce907feb69463d629f
Autor:
Dadasaheb Akolkar, Darshana Patil, Navin Srivastava, Revati Patil, Vineet Datta, Sachin Apurwa, Nitin Yashwante, Raja Dhasarathan, Rahul Gosavi, Jinumary John, Shabishta Khan, Ninad Jadhav, Priti Mene, Dhanashri Ahire, Sushant Pawar, Harshal Bodke, Subhraline Sahoo, Arun Nile, Dinesh Saindane, Harshal Darokar, Pradip Devhare, Ajay Srinivasan, Rajan Datar
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0246048 (2021)
We present data on analytical validation of the multigene variant profiling assay (CellDx) to provide actionable indications for selection of targeted and immune checkpoint inhibitor (ICI) therapy in solid tumors. CellDx includes Next Generation Sequ
Externí odkaz:
https://doaj.org/article/14c1fdb7b51a495288351668340b7646
Autor:
S. Pawar, Rutuja Bhave, Raja Dhasarathan, Mahesh Ukade, Vineet Datta, Chirantan Bose, Harshal Bodke, Ajay Srinivasan, Stefan Schuster, Dadasaheb Akolkar, Shabista Khan, Cynthe Sims, Darshana Patil, Jatinder Bhatia, Vishakha Mhase, Sanket Patil, Rajan Datar, Sachin Apurwa, Samruddhi Raut
Publikováno v:
Cancer Research. 81:PS4-36
Background: Despite the development of Checkpoint Inhibitor Treatments (Immunotherapy) and Targeted anticancer agents, cytotoxic (chemotherapy) agents remain the mainstay of breast cancer treatments. However, treatment failure is often encountered in
Autor:
Shoeb Patel, Stefan Schuster, Revati Patil, Pooja Fulmali, Raja Dhasarathan, Cynthe Sims, Shabista Khan, Darshana Patil, Harshal Bodke, Dadasaheb Akolkar, Vineet Datta, Archana Adhav, Rajan Datar, S. Pawar, Pradip Devhare, Pradip Fulmali, Sachin Apurwa, Ajay Srinivasan, Rohit A. Chougule, Sanket Patil, Vishal Ranjan, Jatinder Bhatia, Pradyumna Shejwalkar, Chirantan Bose
Publikováno v:
Cancer Research. 81:PS3-13
Background: Common modalities for breast cancer screening include self-breast examination (SBE) for detection of palpable lumps as well as Mammography scans for detection of suspicious nodules or masses. While both approaches have low specificity, SB
Autor:
Cynthe Sims, Vineet Datta, Dadasaheb Akolkar, Viwek Mane, Madhavi Apastamb, Sachin Apurwa, Ajay Srinivasan, Ashok Gawai, Tim Crook, Revati Patil, Sanket Patil, Rajan Datar, Vishakha Mhase
Publikováno v:
Cancer Research. 80:P6-10
Background: Chemoresistance in cancer cells is the underlying reason for treatment failure. Real-time monitoring of chemoresistance and response (CRR) is a fundamental but unmet prerequisite of precision oncology. Repetitive invasive biopsies to obta
Autor:
Sewanti Limaye, Simon Chowdhury, Nitesh Rohatgi, Anantbhushan Ranade, Nelofer Syed, Johann Riedemann, Raymond Page, Darshana Patil, Dadasaheb Akolkar, Vineet Datta, Revati Patil, Kiran Bendale, Pooja Fulmali, Pradeep Fulmali, Sachin Apurwa, Stefan Schuster, Sudha S Murthy, Chirantan Bose, Jinumary John, Ajay Srinivasan, Rajan Datar
BackgroundEvaluation of serum prostate specific antigen (PSA) is a part of standard prostate cancer diagnostic work-up in symptomatic males as well as for elective prostate cancer screening in asymptomatic males. The low specificity of serum PSA lead
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76e66d4854a39850b04e17db634193c8
https://doi.org/10.1101/2022.05.11.22274934
https://doi.org/10.1101/2022.05.11.22274934